Downregulation of the ubiquitin-proteasome system in normal colonic macrophages and reinduction in inflammatory bowel disease

Digestion

Volumn 86, Issue 1, 2012, Pages 34-47

  Hetzenecker, A M ^a   Seidl, M C ^a   Kosovac, K ^a   Herfarth, H ^b   Kellermeier, S ^c   Obermeier, F ^a   Falk, W ^a   Schoelmerich, J ^a   Hausmann, M ^c   Rogler, G ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Immunoproteasome; Intestinal macrophages; Proteasome; Tolerance; Ubiquitin

Indexed keywords

MESSENGER RNA; PROTEASOME; UBIQUITIN;

ARTICLE; ATPASE2 GENE; CELL DIFFERENTIATION; CONTROLLED STUDY; CROHN DISEASE; DIVERTICULITIS; DNA MICROARRAY; DOWN REGULATION; FLUOROMETRY; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; INTESTINAL LAMINA PROPRIA MACROPHAGE; INTESTINE CELL; INTESTINE MUCOSA; LMP7 GENE; MACROPHAGE; MECL 1 GENE; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEASOME BETA2 GENE; PROTEASOME BETA5 GENE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UBB GENE; UBE2A GENE; UBE2D2 GENE; UBE2L6 GENE; UBIQUITINATION; ULCERATIVE COLITIS; USP14 GENE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; CELL DIFFERENTIATION; CELLS, CULTURED; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; DIVERTICULITIS; DOWN-REGULATION; HUMANS; INTESTINAL MUCOSA; MACROPHAGES; MICROARRAY ANALYSIS; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; UBIQUITIN; UBIQUITIN THIOLESTERASE; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 84862248525     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000336353     Document Type: Article

References (46)

1. Demartino GN, Gillette TG: Proteasomes: Machines for all reasons. Cell 2007; 129: 659-662.
2. Segref A, Hoppe T: Think locally: Control of ubiquitin-dependent protein degradation in neurons. EMBO Rep 2009; 10: 44-50.
3. Hochstrasser M: Origin and function of ubiquitin-like proteins. Nature 2009; 458: 422-429.
4. Hirsch C, Gauss R, Horn SC, Neuber O, Sommer T: The ubiquitylation machinery of the endoplasmic reticulum. Nature 2009; 458: 453-460.
5. Murata S, Yashiroda H, Tanaka K: Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol 2009; 10: 104-115.
6. Kruger E, Kuckelkorn U, Sijts A, Kloetzel PM: The components of the proteasome system and their role in MHC class I antigen processing. Rev Physiol Biochem Pharmacol 2003; 148: 81-104.
7. Jung T, Catalgol B, Grune T: The proteasomal system. Mol Aspects Med 2009; 30: 191-296.
8. Tu L, Moriya C, Imai T, Ishida H, Tetsutani K, Duan X, Murata S, Tanaka K, Shimokawa C, Hisaeda H, Himeno K: Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection. Eur J Immunol 2009; 39: 3385-3394.
9. Barton LF, Cruz M, Rangwala R, Deepe GS Jr, Monaco JJ: Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection. J Immunol 2002; 169: 3046-3052.
10. Groettrup M, Khan S, Schwarz K, Schmidtke G: Interferon- inducible exchanges of 20S proteasome active site subunits: Why? Biochimie 2001; 83: 367-372.
11. Frisan T, Levitsky V, Polack A, Masucci MG: Phenotype-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines. J Immunol 1998; 160: 3281-3289.
12. Hallermalm K, Seki K, Wei C, Castelli C, Rivoltini L, Kiessling R, Levitskaya J: Tumor necrosis factor- - induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 2001; 98: 1108-1115.
13. Stohwasser R, Kuckelkorn U, Kraft R, Kostka S, Kloetzel PM: 20S proteasome from LMP7 knock out mice reveals altered proteolytic activities and cleavage site preferences. FEBS Lett 1996; 383: 109-113.
14. Basler M, Moebius J, Elenich L, Groettrup M, Monaco JJ: An altered T cell repertoire in MECL-1-deficient mice. J Immunol 2006; 176: 6665-6672.
15. Caudill CM, Jayarapu K, Elenich L, Monaco JJ, Colbert RA, Griffin TA: T cells lacking immunoproteasome subunits MECL-1 and LMP7 hyperproliferate in response to polyclonal mitogens. J Immunol 2006; 176: 4075-4082.
16. Yu X, Kem DC: Proteasome inhibition during myocardial infarction. Cardiovasc Res 2010; 85: 312-320.
17. Testa U: Proteasome inhibitors in cancer therapy. Curr Drug Targets 2009; 10: 968-981.
18. Koreth J, Alyea EP, Murphy WJ, Welniak LA: Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: A review. Biol Blood Marrow Transplant 2009; 15: 1502-1512.
19. Everly JJ, Walsh RC, Alloway RR, Woodle ES: Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662-666.
20. Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J, Jakob C, Sezer O: Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des 2007; 13: 471-485.
21. Letoha T, Feher LZ, Pecze L, Somlai C, Varga I, Kaszaki J, Toth G, Vizler C, Tiszlavicz L, Takacs T: Therapeutic proteasome inhibition in experimental acute pancreatitis. World J Gastroenterol 2007; 13: 4452-4457.
22. Rogler G, Hausmann M, Vogl D, Aschenbrenner E, Andus T, Falk W, Andreesen R, Scholmerich J, Gross V: Isolation and phenotypic characterization of colonic macrophages. Clin Exp Immunol 1998; 112: 205-215.
23. Salomons FA, Acs K, Dantuma NP: Illuminating the ubiquitin/proteasome system. Exp Cell Res 2010; 316: 1289-1295.
24. Sorokin AV, Kim ER, Ovchinnikov LP: Proteasome system of protein degradation and processing. Biochemistry (Mosc) 2009; 74: 1411-1442.
25. Navon A, Ciechanover A: The 26 S proteasome: From basic mechanisms to drug targeting. J Biol Chem 2009; 284: 33713-33718.
26. Loureiro J, Ploegh HL: Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. Adv Immunol 2006; 92: 225-305.
27. Makala LH, Nishikawa Y, Suzuki N, Nagasawa H: Immunology. Antigen-presenting cells in the gut. J Biomed Sci 2004; 11: 130-141.
28. Pavli P, Maxwell L, Van de Pol E, Doe F: Distribution of human colonic dendritic cells and macrophages. Clin Exp Immunol 1996; 104: 124-132.
29. Smythies LE, Sellers M, Clements RH, Mosteller
30. Barnum M, Meng G, Benjamin WH, Orenstein JM, Smith PD: Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005; 115: 66-75.
31. Carlsen HS, Yamanaka T, Scott H, Rugtveit J, Brandtzaeg P: The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria. Inflamm Bowel Dis 2006; 12: 1013-1024.
32. Spottl T, Hausmann M, Kreutz M, Peuker A, Vogl D, Scholmerich J, Falk W, Andreesen R, Andus T, Herfarth H, Rogler G: Monocyte differentiation in intestine-like macrophage phenotype induced by epithelial cells. J Leukoc Biol 2001; 70: 241-251.
33. Rugtveit J, Bakka A, Brandtzaeg P: Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD). Clin Exp Immunol 1997; 110: 104-113.
34. Rogler G, Hausmann M, Spottl T, Vogl D, Aschenbrenner E, Andus T, Falk W, Scholmerich J, Gross V: T-cell co-stimulatory molecules are upregulated on intestinal macrophages from inflammatory bowel disease mucosa. Eur J Gastroenterol Hepatol 1999; 11: 1105-1111.
35. Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SH, Schmidt-Ullrich R, Steinhoff U: Proteasome- mediated degradation of I - B - and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006; 116: 3195-3203.
36. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J, Gross V: Nuclear factor - B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115: 357-369.
37. Kosovac K, Brenmoehl J, Holler E, Falk W, Schoelmerich J, Hausmann M, Rogler G: Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. Inflamm Bowel Dis 2010.
38. Colpaert S, Vastraelen K, Liu Z, Maerten P, Shen C, Penninckx F, Geboes K, Rutgeerts P, Ceuppens JL: In vitro analysis of interferon gamma (IFN- -) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease. Eur Cytokine Netw 2002; 13: 431-
39. Sasaki T, Hiwatashi N, Yamazaki H, Noguchi M, Toyota T: The role of interferon - in the pathogenesis of Crohn's disease. Gastroenterol Jpn 1992; 27: 29-36.
40. Guarner F: What is the role of the enteric commensal flora in IBD? Inflamm Bowel Dis 2008; 14(suppl 2):S83-S84.
41. Murphy SJ, Ullman TA, Abreu MT: Gut microbes in Crohn's disease: Getting to know you better? Am J Gastroenterol 2008; 103: 397-398.
42. Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S: Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 2006; 55: 1760-1767.
43. Tien MT, Girardin SE, Regnault B, Le Bourhis L, Dillies MA, Coppee JY, Bourdet- Sicard R, Sansonetti PJ, Pedron T: Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol 2006; 176: 1228-1237.
44. Bentz S, Hausmann M, Piberger H, Kellermeier S, Paul S, Held L, Falk W, Obermeier F, Fried M, Scholmerich J, Rogler G: Clinical relevance of IgG antibodies against food antigens in Crohn's disease: A double-blind cross-over diet intervention study. Digestion 2010; 81: 252-264.
45. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102: 448-455.
46. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M: Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26: 934-938.